


# AMENDMENTS TO THE CLAIMS


Claims 1-16 (*Previously cancelled*)

Claim 17. (*Currently amended*) A compound having the structure:




~~or an optical isomer, diastereomer, enantiomer, or pharmaceutically acceptable salt, or amide, ester, or imide susceptible to being cleaved *in vivo* by a mammalian subject to yield the compound, wherein:~~

- (a)  $A^1$  and  $A^2$  are each, independently, selected from the group consisting of a hydrogen atom and a group having the structure:



with the proviso that at  $A^1$  and  $A^2$  are not both hydrogen atoms, and wherein:

- (i) each  $R^1$  is independently selected from the group consisting of a hydrogen atom and a hydroxyl group;
- (ii)  $x$  is 0 or 1;
- (iii) each  $R^2$  is independently selected from the group consisting of:




wherein:

- (a) a is at least 2;
- (b) b is at least 2;
- (c) c is 1 to 3;
- (d) d is 1 to 3; and
- (e)  $R^{12}$  and  $R^{13}$  are each independently selected from the group consisting of hydrocarbon groups and substituted hydrocarbon groups; and

~~(iv)  $D^1$  and  $D^2$  are each independently selected from the group consisting of  $C(O)$  and  $NH$ ; with the proviso that wherein when  $D^1$  is  $NH$  then  $D^2$  is  $C(O)$ , and wherein when  $D^2$  is  $NH$  then  $D^1$  is  $C(O)$ ;  $D^1$  is  $-C(O)-$ ; and~~

(v)  $D^2$  is  $-NH-$ .

(b)  $A^3$  has the structure:



wherein:

- (i) each  $R^1$  is independently selected from the group consisting of a hydrogen atom and a hydroxyl group;
- (ii) t is from 0 to 6;

(iii)  $D^4$  is  $-\text{CH}(\text{R}^1)-$  ;

(iv)  $D^5$  is  $-\text{OR}^6$  ; and

(v)  $\text{R}^6$  is selected from the group consisting of a carbocyclic group, a substituted carbocyclic group, an aromatic group, and a substituted aromatic group.

Claim 18. (*Previously added*) The compound according to Claim 17 wherein x is 1.

Claim 19. (*Previously added*) The compound according to claim 17 wherein x is 0. Claim 20. (*Currently cancelled*)

Claim 21. (*Currently cancelled*)

Claim 22. (*Currently cancelled*)

Claim 23. (*Previously amended*) The compound according to Claim 17 wherein t is 0 to 2.

Claim 24. (*Previously added*) The compound according to Claim 17 wherein  $\text{R}^6$  is a substituted aromatic group.

Claim 25. (*Previously added*) A composition comprising:

(a) the compound according to Claim 1; and

(b) a pharmaceutically acceptable carrier.

Claim 26. (*Previously added*) A method selected from the group consisting of treating multidrug resistance, inhibiting transport protein activity, combinations thereof, comprising administering to a mammal in need of such treatment or inhibition an effective amount of the composition according to Claim 2.